Objective. Assessing statistical rates and outcomes of ocular iris and ciliary body melanoma treatment in the Republic of Belarus and by global data.
Materials and methods. The data from Belarusian Cancer Registry and case histories with clinically and pathologically verified diagnoses of iris and ciliary body melanoma (C69.4, ICD—10) over the period of 2003—2017 were included in the study. The study enrolled 79 patients. Of them, thirteen (16.5%) persons had ocular iris melanoma (Group 1); 50 patients (63.3%) — ciliary body melanoma (Group 2); sixteen subjects (20.2%) — ocular iris and ciliary body melanoma (Group 3). The incidence and mortality assessment was based on the analysis of the absolute numbers of persons taken ill, crude values calculated per 1,000,000 population. The disease-specific 5-year survival rate was used for survival calculation.
Results. In Groups 1 and 2, the incidence among women was on the average 1.6-fold more common than among men. The mean age of patients with iris melanoma was 45—49 years; the growth in the number of ciliary body melanoma patients began at 40 years, its peak being at the age 75—79 years; the incidence peak in Group 3 is at 65—69 years. In Group 1, 76.9% of the disease cases was diagnosed at the disease stage II; in Group 2, 40.0% of the disease cases were identified at the disease stage II and in 32.0% of cases — at the disease stage III. In Group 3, melanoma was revealed at stages II and of III pf progressing. In Group 3, the number of women was 3 times larger than that of men, accounting for 75%. Of 50 patients with ciliary body melanoma, progression occurred in 12 (24.0%) subjects, in Group 3 — in four (25.0%) of patients. No recurrence or disease progression was noted with iris melanoma.
Conclusion. Ocular iris and ciliary body melanoma incidence rates were 0.2‰ to 0.4‰. The cumulative disease-specific 5-year survival rates were 100% for iris melanoma, 75% for ciliary body melanoma, and 83.3% for iris and ciliary body melanoma. Iris melanoma patients underwent iridectomy, those with the tumor site in the ciliary body — cyclectomy in the cases of the tumor base exceeding 1 cm. When the tumor base exceeded 1 cm and/or the tumor invaded the choroid, either enucleation or brachytherapy was performed. The presented data from Belarusian Cancer Registry and the data from global sources are comparable.Ключевые слова:
Автор(ы): L. V. Naumenko